Avidity’s early-phase data for rare muscle disease drug spur registrational plans

Ayisha Sharma

News Reporter

Avidity Biosciences’ antibody oligonucleotide conjugate has shown signs of efficacy in an early-stage test in patients with a rare muscle-wasting disease.

Just last month, Leerink …

Sign up to read this article for free.

Get free access to a limited number of articles, plus choose newsletters to get straight to your inbox.

BECOME A PREMIUM SUBSCRIBER

Avidity’s early-phase data for rare muscle disease drug spur registrational plans

Ayisha Sharma

News Reporter

Sign up to read this article for free.

Director of IT, Security

Viridian Therapeutics

Waltham, MA, USA

Exclusive: Influential Democrat will oppose Biosecure Act ahead of House vote

Astellas CEO talks future beyond Xtandi as Japanese drugmaker puts roots in Boston

BridgeBio sticks to script for ATTR-CM as Alnylam cleans up ‘typo’ snafu

Roche's Spark loses CEO to RNA upstart; Ex-Elevation Oncology chief takes over at Affimed

Lilly inks obesity deal with seed-stage RNA startup as its genetic medicines effort enters the spotlight

How to secure full enrollment and a 30x ROI: A conversation with the CEO of the boutique enrollment agency doing just ...

Avid­i­ty’s ear­ly-phase da­ta for rare mus­cle dis­ease drug spur reg­is­tra­tional plans

News Reporter

Sign up to read this article for free.

Viridian Therapeutics

Waltham, MA, USA

Avidity’s early-phase data for rare muscle disease drug spur registrational plans